<DOC>
	<DOCNO>NCT02554942</DOCNO>
	<brief_summary>This study evaluate safety subcutaneous ( SC ) epoetin beta ( NeoRecormon ) adult solid tumor treat platinum-based chemotherapy capable induce anemia . The anticipated time study treatment 16 week , target sample size approximately 208 individual .</brief_summary>
	<brief_title>A Study Epoetin Beta ( NeoRecormon ) Participants With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adults least 18 year age Presence solid tumor ( ) Receiving platinumbased therapy capable induce anemia Red blood cell transfusion within 7 day prior study drug Relevant acute chronic bleed require therapy within 3 month prior study drug Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>